D. Arpin

972 total citations
43 papers, 687 citations indexed

About

D. Arpin is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, D. Arpin has authored 43 papers receiving a total of 687 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 23 papers in Oncology and 9 papers in Surgery. Recurrent topics in D. Arpin's work include Lung Cancer Research Studies (18 papers), Lung Cancer Treatments and Mutations (18 papers) and Lung Cancer Diagnosis and Treatment (12 papers). D. Arpin is often cited by papers focused on Lung Cancer Research Studies (18 papers), Lung Cancer Treatments and Mutations (18 papers) and Lung Cancer Diagnosis and Treatment (12 papers). D. Arpin collaborates with scholars based in France, United States and Luxembourg. D. Arpin's co-authors include David Pérol, C. Carrié, L. Falchero, M. Pérol, L. Claude, C. Ginestet, Michel Vincent, Isabelle Martel‐Lafay, Jean-François Cordier and I. Martel and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

D. Arpin

40 papers receiving 676 citations

Peers

Countries citing papers authored by D. Arpin

Since Specialization

Citations

This map shows the geographic impact of D. Arpin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Arpin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Arpin more than expected).

Fields of papers citing papers by D. Arpin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Arpin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Arpin. The network helps show where D. Arpin may publish in the future.

Co-authorship network of co-authors of D. Arpin

This figure shows the co-authorship network connecting the top 25 collaborators of D. Arpin. A scholar is included among the top collaborators of D. Arpin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Arpin. D. Arpin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Rebiopsy Feasibility and Clinical Impact on Metastatic Non-Small-Cell Lung Cancer With EGFR/ALK/ROS Oncogenic Driver Progression After Optimal Targeted Therapy: A Multicenter Real-World Analysis 2025 ·Clinical Lung Cancer ·(unknown), (unknown), Isabelle Monnet, Charles Ricordel, L. Bigay-Gamé, (unknown), (unknown), (unknown), (unknown), Aurélie Swalduz, (unknown), H. Doubre, (unknown), D. Arpin, Hugues Morel, Rémi Veillon, Bénédicte Clarisse, C. Chouaïd, Laurent Greillier, (unknown)	0
2	Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06–2018 study) 2024 ·Lung Cancer ·(unknown), Pascale Tomasini, Emmanuelle Dantony, (unknown), Charles Ricordel, L. Bigay-Gamé, D. Arpin, Hugues Morel, Rémi Veillon, (unknown), (unknown), P. Fournel, A. Vergnenègre, (unknown), Fabien Subtil, Bénédicte Clarisse, C. Decroisette, C. Chouaïd, Laurent Greillier, Olivier Bylicki	4
3	Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors 2016 ·Lung Cancer ·Thomas Walter, David Planchard, (unknown), Jean‐Yves Scoazec, P.-J. Souquet, (unknown), J. Guigay, Valérie Hervieu, A. Berdelou, Michel Ducreux, D. Arpin, Catherine Lombard‐Bohas, Éric Baudin	19
4	Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study 2015 ·Targeted Oncology ·J.B. Auliac, Charles Fournier, Clarisse Audigier-Valette, M. Pérol, (unknown), F. Viñas, (unknown), (unknown), R. Corre, G. Le Garff, P. Fournel, Nathalie Baize, R. Lamy, A. Vergnenègre, D. Arpin, Benôıt Marin, C. Chouaïd, R. Gervais	15
5	Routine EGFR Molecular Analysis in Non-Small-Cell Lung Cancer Patients is Feasible: Exons 18–21 Sequencing Results of 753 Patients and Subsequent Clinical Outcomes 2013 ·Lung ·M. Locatelli-Sanchez, S. Couraud, D. Arpin, R Riou, Pierre‐Paul Bringuier, Pierre-Jean Souquet	40
6	Embolie gazeuse de révélation tardive après ponction transpariétale pulmonaire 2012 ·La Revue de Médecine Interne ·Olivier Bylicki, (unknown), (unknown), (unknown), (unknown), M. Pérol, D. Arpin	2
7	Traitement de maintenance dans les cancers bronchiques non à petites cellules métastatiques : une révolution conceptuelle ? 2011 ·La Presse Médicale ·M. Pérol, D. Arpin	2
8	Diffuse Interstitial Lung Disease Linked to Vandetanib 2011 ·Clinical Lung Cancer ·(unknown), D. Arpin, (unknown), M. Pérol	2
9	Predictive Factors of Late Radiation Fibrosis: A Prospective Study in Non–Small Cell Lung Cancer 2010 ·International Journal of Radiation OncologyBiologyPhysics ·R. Mazeron, B. Étienne-Mastroïanni, David Pérol, D. Arpin, Michel Vincent, L. Falchero, Isabelle Martel‐Lafay, C. Carrié, L. Claude	48
10	La stratégie de maintenance en première ligne de traitement dans les cancers bronchiques non à petites cellules avancés 2010 ·Revue des Maladies Respiratoires Actualités ·M. Pérol, (unknown), D. Arpin	1
11	Bevacizumab et cancer bronchique non à petites cellules : une nouvelle étape ? 2009 ·Revue des Maladies Respiratoires ·M. Pérol, D. Arpin	0
12	Facteurs prédictifs de la pneumopathie radique aiguë 2009 ·Revue de Pneumologie Clinique ·D. Arpin, Marc-André Mahé, Vincent Servois, L. Claude	8
13	[Tyrosine kinase inhibitors in the management of non-small cell lung cancer]. 2007 ·PubMed ·M. Pérol, D. Arpin	2
14	Prospective evaluation of early lung toxicity following three-dimensional conformal radiation therapy in non–small-cell lung cancer: preliminary results 2000 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), L. Falchero, (unknown), M. Pérol, D. Arpin, Michel Vincent, (unknown), (unknown), C. Ginestet, (unknown), David Pérol, C. Carrié	43
15	Small-cell lung cancer: Patients included in clinical trials are not representative of the patient population as a whole 1999 ·Annals of Oncology ·Vincent Cottin, D. Arpin, Christine Lasset, J.-F. Cordier, J Brune, Franck Chauvin, V. Trillet-Lenoir	61
16	Clinical and radiological aspects of Villaret's syndrome 1996 ·Clinical Neurology and Neurosurgery ·(unknown), P. Petiot, D. Arpin, Jean‐François Mornex, F. Mornex, (unknown), J Brune, G Aimard	9
17	The limits of chemotherapy dose intensification using Granulocyte Colony Stimulating Factor alone in extensive small cell lung cancer 1996 ·Lung Cancer ·V. Trillet-Lenoir, (unknown), D. Arpin, C. Lombard Bohas, R Riou, I. Court-Fortuné, (unknown), M. Pérol, J.-F. Cordier	6
18	Optimal delivery of dose in cancer chemotherapy with the support of haematopoietic growth factors 1993 ·European Journal of Cancer ·V. Trillet-Lenoir, D. Arpin, J Brune	3
19	Contracture test and histologic and histochemical analyses of muscle biopsy specimens from horses with exertional rhabdomyolysis 1990 ·Journal of the American Veterinary Medical Association ·(unknown), D. Arpin, George H. Cardinet	12
20	Neuromuscular and cardiovascular effects of atracurium in ponies anesthetized with halothane 1986 ·American Journal of Veterinary Research ·(unknown), G. Howitt, D. Arpin	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact